Adding local treatment to hormone therapy for advanced prostate cancer

Plain-English translation of NCT06832774 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether combining novel hormone therapy with local treatment (like radiation or surgery targeting specific tumors) works better than hormone therapy alone for men with advanced prostate cancer. Researchers will use a special imaging scan called PSMA PET/CT to identify which patients have active cancer remaining after 8 months of hormone therapy, then randomly assign those patients to receive either the hormone therapy alone or the hormone therapy plus additional local treatment to see which approach delays cancer progression and extends survival.

Doctors aren't yet sure about the best way to treat advanced prostate cancer when it continues to show active disease despite hormone therapy. This trial is designed to fill that gap by testing whether targeting the remaining cancer spots with additional local treatment — in addition to the medication — improves outcomes for patients.

Do you qualify?

You likely qualify if…

you are a male patient 18 years or older
you have been newly diagnosed with advanced prostate cancer that has spread to other parts of your body and is hormone-sensitive
you have been on hormone therapy for about 8 months and still have active cancer visible on your PSMA PET/CT scan
you have not received any other prostate cancer treatments before starting this trial
you are in good enough health to participate (your doctor rates your overall condition as 0, 1, or 2 on a standard scale)
you are expected to live for at least 2 more years

You likely don't qualify if…

you have been diagnosed with another active cancer in the past 2 years (except certain skin cancers)
your prostate cancer biopsy showed rare, aggressive cell types such as sarcomatoid cells or neuroendocrine cells
you have severe medical complications, a weakened immune system, severe mental illness, or are unable to follow the study plan
you are currently enrolled in another clinical trial for prostate cancer
your doctor believes that participating in this trial would not be in your best interest

What participation looks like

You will receive hormone therapy for about 8 months. Then doctors will perform a special imaging scan (PSMA PET/CT) to see if any active cancer remains. If active cancer is still present, you'll be randomly assigned to either continue hormone therapy alone or receive hormone therapy plus local treatment (such as targeted radiation or surgery) to the remaining cancer spots. The study will follow your progress to see how well the treatment works and how long you survive.

Adding local treatment to hormone therapy for advanced prostate cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)